Et klinisk forsøg med SOMAVERT til diabetiske patienter behandlet med enten insulin eller orale hyperglykæmiske lægemidler, viste en risiko for hypoglykæmi i denne population.
The study conducted with SOMAVERT in diabetic patients treated either by insulin or by oral hypoglycaemic medicinal products revealed the risk of hypoglycemia in this population.